One trial, thirty people, and 2027
Let me say it straight away: whether taurine slows the course of Parkinson’s has never been studied. You probably knew that already — otherwise your doctor would have told you.
Since late 2025 one trial has been running in which thirty people with Parkinson’s take a blend of six amino acids, taurine among them, and it measures nutritional status and muscle function rather than whether the disease slows down — with no result due before the end of 2027.1
From here on it is about what has been measured. Why I write about things like this, and what bar I hold them to, is on the front page.
Taurine
Not an ordinary amino acid, not a building block of protein. But one of the most abundant free compounds in your brain.
- You make it yourself, but not much. Roughly 50 to 125 mg a day, from cysteine. The rest comes from food: 123–178 mg a day on an average Western diet.2
- Plants contain none of it, not even traces. It is in meat, fish and shellfish. Vegans have measurably lower levels.3
- In Japan it is a medicine. Approved for heart failure, 1 gram three times a day. In Europe and the US it is a supplement.4
- It lowers blood pressure and blood sugar. A hundred and twenty people whose blood pressure sat just under the threshold took 1.6 grams of taurine a day for twelve weeks, or a dummy capsule. Measured in the clinic, their upper reading fell seven points, against just over two on the dummy.5,6
- In Parkinson’s it is lower in the spinal fluid. And that relationship tracks the severity of the damage.7
- The stated dose has been assessed directly. The Norwegian regulator looked at 750 to 1000 mg a day and judged it unlikely to harm adults.8,9
How to read this
Black blocks tell the story in plain language. Read only those and you have the whole argument.
Evidence sits collapsed and holds the scientific detail with numbered sources. Open whatever you want to check — or leave it all shut, you miss nothing by doing so.
One thing up front. This is an explanation of mechanisms — not medical advice and not a treatment plan.
Taurine is not a replacement for any Parkinson’s medication. Levodopa and the drugs around it do something taurine demonstrably does not. Anyone with Parkinson’s who changes what they take should discuss it with their neurologist — if only because they track the symptoms and will be first to see if anything shifts.
This is the whole story, in seven steps
Read only this and you have the core. The rest is how we know it.
- In Parkinson’s, dopamine neurons die in a small nucleus: the substantia nigra.
- In mice, taurine protects those neurons. They are given a poison that wrecks the nigra, and the animals given taurine alongside it keep most of their neurons.
- It does not protect them itself. It calms the inflamed immune cells beside them — and where those are absent, taurine does nothing at all.
- In people with early Parkinson’s there is less taurine in the spinal fluid than in people without the disease.
- And within that group: the less taurine, the weaker the dopamine signal on the scan and the less people could still do unaided.
- That swallowed taurine reaches the brain has been measured in humans. Whether 850 mg is enough has not — and that is the open question.
- On the way, part of your taurine ends up in your colon, where what becomes of it depends on what you feed your gut bacteria. That is the dial you can turn today.
The basics, briefly
Somewhere in the middle of your brain sits a small area of dark-coloured cells: the substantia nigra, the black substance.
Those cells make dopamine and signal it on to an area that drives your movement. As long as that signal is there, you never have to think about standing up, walking, or doing up your coat.
In Parkinson’s those cells die, slowly and over years, and by the time the first tremor or stiffness is noticeable, a large share of them has already gone.
Levodopa tops up the missing dopamine. That often works well for years — but it does not stop the cells from dying.
Your brain has an immune system of its own. The cells that run it are called microglia.
They clear up, repair and keep things tidy, but they also have an aggressive setting meant for infection: alarm, inflammation, attack. If that setting stays on with nothing to clear up, they start causing damage instead of repairing it.
In Parkinson’s they are switched on right around the dying dopamine neurons. There they pump out oxygen radicals and inflammatory compounds, and the dopamine neuron next to them takes the brunt of it.
That is where taurine steps in: it takes the microglia out of that setting, so the dopamine neuron beside them has less to endure.
Taurine is often called “an amino acid”. That is not quite right, and the difference matters later.
Ordinary amino acids are the building blocks of protein. Taurine is not — it appears in no protein in your body. It floats around free, and in large amounts precisely in your brain, heart and eyes.
You make it yourself from cysteine, but not much. The rest comes from meat, fish and shellfish. Plants contain none.
More precisely
Taurine is a β-amino sulfonic acid, meaning it carries a sulfonic acid group where an ordinary amino acid has a carboxyl group, and that its amino group sits on the β-carbon. That is why it will not fit into a peptide chain. Adults make it themselves from cysteine, via cysteine dioxygenase and cysteine sulfinic acid decarboxylase, on the order of 50 to 125 mg a day against a dietary intake of 40 to 400 — enough to call it conditionally essential.2 Its main known functions are bile acid conjugation, osmoregulation, membrane stabilisation and modulation of calcium flux.
In neural signalling taurine behaves as an inhibitor, being a weak agonist at GABAA and glycine receptors and therefore hyperpolarising and anti-excitotoxic.10 That is the opposite direction from the widely repeated claim that taurine “raises dopamine”. Why that claim does not hold is in PART V.
The indication in humans
In Parkinson’s, taurine in the spinal fluid runs lower than in people without the disease. And within a group of patients, more taurine goes together with less damage.
In Japan, Mimori and colleagues took spinal fluid from 45 people with early Parkinson’s. Those with more taurine in that fluid had a more favourable brain scan: a stronger dopamine transporter signal, better movement, and more things they could still do themselves.
That probably says more about the inflammatory setting of the cells around the neuron than about the neuron itself, though it may just as well run the other way and a damaged brain simply retains less taurine.
It has not stopped with that one group. A meta-analysis pooling the earlier work found taurine lower in spinal fluid as well — and not in the tube of blood from those same people. And in 2026 taurine surfaced again, in two separate groups of over a hundred and fifty untreated patients with as many controls beside them, as one of the most stable compounds on which the two groups differed.
Macaques that had been given MPTP diverged sharply: some never fell ill, some recovered, some stayed severely affected. The animals that came through it had more taurine in their brains — more than the sick animals, and more than the monkeys that had never been given the toxin, and most clearly in a region where no cells had died at all.
For a simple depletion story that is the wrong way round: there, taurine would sink as more of the tissue was lost.
Evidence
This concerns 45 drug-naïve patients with a mean age of 68.6, in whom amino acids were measured in both plasma and cerebrospinal fluid, alongside dopamine transporter imaging. Higher CSF taurine went with better preserved DAT binding and with better motor and daily-living scores; in multivariate analysis CSF taurine remained an independent factor.7
That fits the wider picture. A meta-analysis of amino acids as biomarkers found taurine lower in cerebrospinal fluid in Parkinson’s, but no significant difference in serum or plasma.11 The signal sits in the compartment that matters, not in the tube of blood taken at the surgery.
In 2026 a broad metabolomics study was added to that, with two independent cohorts: 153 drug-naïve de novo patients against 153 matched controls, and 135 against 135. Taurine was among the metabolites contributing most stably to the separation and stayed selected when the analysis was restricted to drug-naïve participants only.12 As far as I can tell the accessible main text does not give the direction: whether plasma taurine in these patients was higher or lower is not in it. What it does show is taurine standing out again, in two groups at once, and not as a by-product of medication.
And here is why it matters that these people were not yet on medication. In other work plasma taurine in Parkinson’s patients was lower than in controls and tracked motor severity — but treated patients had lower levels than untreated ones, with a negative correlation to cumulative levodopa dose that survived adjustment.13 So part of what you measure in blood is a medication effect, not a disease effect.
What this design cannot do is separate cause from effect: a cross-sectional measurement shows that two things move together and not which one is driving, so low taurine could just as easily be a consequence of the neurodegeneration as a cause of it.
The sharpest counterweight comes from a primate study in which the researchers split their exposed animals into four groups rather than two. They gave one group of macaques MPTP, sorted those afterwards by how it had turned out — never fell ill, recovered, moderate and severe parkinsonism — placed alongside them animals that had never been given the toxin, and only then measured the taurine, in caudate, putamen, primary motor cortex and prefrontal cortex. Taurine was higher in the asymptomatic and recovered animals than in both the parkinsonian animals and the controls, most clearly in cortex. They were deliberately looking for brain constituents that could not themselves be a consequence of the degenerative process.14
Three limits go with it. No taurine was administered, so it stays a correlation, only then in a far better species and in tissue rather than in fluid. Taurine was not the only difference either, because MAO B was higher in the severely affected animals, and MAO B is precisely the enzyme that turns MPTP into the compound that kills the cells — so the authors end up concluding two things at once, less protective taurine and more bioactivating MAO B. And measurement was after the fact, so whether the taurine difference predated the exposure or is a response to it cannot be read off these data.
For the direction question it helps regardless: taurine high in tissue where there was no damage, in animals that did get the toxin. But the real answer to “does taurine do something, or does it merely happen alongside?” only comes when you take it away, and that is the next part.
Not measured: whether the low taurine is a cause or a consequence.
What happens when you take the microglia away
In mice, taurine protects the dopamine neurons in the substantia nigra. Che and colleagues injected their animals with two pesticides for six weeks, after which those neurons died and the mice walked worse. The animals given taurine as well kept most of those neurons.
They did something else alongside it in 2018. They put brain cells from rat embryos in a dish, removed the microglia from half of them, and then gave both groups the same poison and the same taurine.
Without microglia the poison already did less damage — so those cells play a part in the death of the dopamine neuron. And that is exactly where there was nothing left for taurine to do: it protected only in the dishes that had microglia in them.
So taurine does not protect the dopamine neuron directly. It inhibits the cells that damage it, and where those are absent there is nothing for it to inhibit.
What it inhibits there was measured in those same mice: the radical machine called NOX2, and the inflammatory signals that come on alongside it. Taurine inhibits both. The attack mode subsides while the clean-up mode stays in place, so it is not a general brake on the immune system.
That route is apparently not a mouse peculiarity. In 2022 Keeney and colleagues examined the substantia nigra of people who had died with Parkinson’s, and found precisely the enzyme taurine inhibited in the mouse — NOX2 — highly active, in the dopamine neurons themselves as well as the microglia around them. In the faster animal models they set alongside it, only the NOX2 in the dopamine neuron was active, which indicates it comes before the glia.
Taurine did not appear in that work. What it does do is make the target human: the junction taurine acts on in the mouse also sits in the brains of people who actually had the disease.
Evidence
Che picked paraquat and maneb, two pesticides used alongside each other on farms, and gave them to C57BL/6J mice twice a week for six weeks at 10 and 30 mg/kg. That is a much slower model than the acute injection these experiments usually run on, and presumably it was chosen for that reason, since someone exposed to pesticides in a field does not take them in all at once either. The taurine went in thirty minutes before each exposure, 150 mg/kg into the abdomen.15
What they then counted is the endpoint that matters, namely the TH⁺ neurons in the substantia nigra pars compacta, blinded, on coded slides and in every third serial section. A formal stereological estimator it is not, but it is the measurement the weaker studies skip. At 2, 4 and 6 weeks they watched the loss climb, the animals given taurine kept significantly more of their neurons, and the gait analysis moved with it — stride length and distance covered.
High-molecular-weight α-synuclein bands also fell, though that is probably an outcome rather than a mechanism, since nobody tested whether taurine binds or inhibits α-synuclein directly. The parsimonious reading seems to me that less oxidative damage yields less clumping downstream.
What taurine switched off in those animals they measured as well. It inhibited NADPH oxidase, visible as less membrane translocation of p47phox, less gp91phox and less superoxide, and it inhibited the NF-κB route, visible as less phosphorylation of p65, IκBα and IKKα. The M1 markers iNOS, TNFα and IL-1β fell while the M2 markers stayed unchanged, which seems to indicate that taurine takes out the inflammatory setting without driving up the clean-up setting.
The design matters here, because the depletion experiment was not in the mice. They ran it in primary midbrain cultures from rat embryos (E14), from which the microglia were removed with leucine methyl ester — clearing more than 99.9%. In those cultures taurine’s protective effect on the TH⁺ neurons was afterwards completely gone.15
That figure alone misleads without the other one. With microglia present, 49.4% of the TH⁺ neurons were lost, and taurine brought that down to 29.2% at 25 µM and 8.2% at 50 µM. Take the microglia out and the loss caused by the poison itself already fell back in part — the authors call it a partial attenuation and give no percentage for it, so the two conditions cannot be weighed against each other.
And there a question forces itself on you: if taurine works only through microglia, how can it prevent more loss than removing those same microglia does? Probably because a depletion experiment gives no upper bound at all. Microglia do two things at once — they cause damage and they clear up — and whoever removes them removes both. Taurine leaves them in place and takes out only the attack mode; that is precisely what Che measured above when the M1 markers fell while the M2 markers did not move. A cell you convert can therefore end up better than a cell that is gone. That comparison was not measured, as it would require laying both conditions side by side.
What follows regardless is the narrower fact this part rests on: without microglia, taurine does nothing. And the poison damaging neurons even without those cells means microglia amplify the damage rather than cause it — so taurine acts on that amplification, not on the poison.
So this is not a third arm of the same mouse experiment but a second system: different species, embryonic tissue, outside the body. A depletion in a living animal would have been stronger. What there is instead is an effect in a living animal plus a separate test of necessity pointing the same way — and as far as I can tell it is the only experiment showing a mechanism rather than a correlation.
Microglia are the best-studied glial cell here, but not the only one involved. In MPP⁺-exposed primary astrocytes and MPTP mice the picture fitted suppression of astrocytic mitochondrial stress and inflammatory signalling — astrocytes were not removed or blocked there, so “the protection ran through astrocytes” is not what it says.16 In the rotenone model taurine suppressed activation of microglia and astrocytes side by side.17 So “taurine acts on the inflammatory cells around the dopamine neuron” holds; “taurine works exclusively through microglia” is too narrow — though Che’s depletion experiment remains the only one that actually removes a route.
NF-κB recurs in Che (mouse microglia), in Moon (astrocytes) and in the rotenone work. And the node is not rodent-specific — for NOX2 the human bridge is the most direct. In postmortem substantia nigra from people with Parkinson’s, NOX2 was highly active, in dopamine neurons as well as microglia. In acute and sub-acute animal models only neuronal NOX2 was active, suggesting the dopamine neuron goes first and the glia follow — a self-reinforcing loop rather than “it starts in the microglia”.18 Here too, no taurine was involved.
An adjacent human network has been mapped separately. In human neuronal and microglial cell lines and in iPSC-derived dopaminergic neurons and microglia, α-synuclein aggregates damage the mitochondria, after which mitochondrial DNA leaks into the cytosol and the cGAS–STING–NF-κB–IRF3 route is activated; that promotes tunnelling nanotubes and transfer of α-synuclein and damaged mitochondria between neurons and microglia.19
The hard limit alongside it: no taurine was used in that study. It therefore proves nothing about taurine. And it is not the same switch as Che’s: Che measured NOX2 and the IKK–IκB–NF-κB axis, Chakraborty manipulated cGAS/STING. What both human studies together do show is that the inflammatory node taurine acts on in the mouse exists in human dopamine neurons and microglia. That is foundation, not roof.
The rest of the animal work, ranked by strength
One strong study is not proof. This is what else is out there, ordered by how hard the endpoint is:
| Study | Model | Measured | What it is worth |
|---|---|---|---|
| Che 201815 | Paraquat + maneb, mouse | Neuron counts in the nigra, gait, α-synuclein, depletion test | Strongest; shows a mechanism |
| Zhu 202617 | Rotenone, mouse | Dopamine neurons, glia, gut and blood-brain barrier, gut flora | Strong; independent second model |
| Cui 202320 | MPTP, mouse | Gut flora, serum taurine, movement, dopamine neurons | Strong, but no faecal transplant |
| Wang 202221 | Paraquat, mouse | Neuron counts in the nigra, striatal dopamine | Usable; the PI3K/Akt direction is odd |
| Abuirmeileh 202122 | 6-OHDA, rat | Rotation behaviour, dopamine by HPLC | Behaviour improved, dopamine not significantly |
| Onuelu 202523 | Rotenone, mouse | Behaviour and markers in homogenate | Weak; do not lean on it |
| Navneet 200824 | MPTP, mouse — taurine after the toxin | Striatal dopamine (HPLC), radicals in mitochondria | Negative; no recovery |
The bottom three belong here precisely because they do not play along. In the rat study the behaviour improved while the fall in dopamine was not significantly reversed. The rotenone study says rats in its title and mice in its methods section — anyone taking both at their word has to assume the animals changed species somewhere between the abstract and the cage. It also finds no dose-response relationship, and looks not at the substantia nigra but at the prefrontal cortex.
And then Navneet, the one outright negative study in the file. Taurine did not reverse the fall in dopamine after MPTP, scavenged no hydroxyl radicals in isolated mitochondria, and without any toxin even produced a small drop in striatal dopamine.24 That bounds any simple account in which taurine is a radical scavenger everywhere.
One difference is decisive though, and it sits in the methods: here the taurine started after the second MPTP injection, whereas Che and Moon dosed beforehand. So this is a treatment experiment, not a prevention one. It also ran six animals per group and measured only neurotransmitters at four days — no cell counts. That makes it no evidence that 850 mg orally is harmful; it is a reason not to read “taurine protects” as a general property.
And then the limit of all of it: these are toxin models. You poison a mouse, you see whether a compound damps it down, and that is not a model of the slow human disease — the history of neuroprotectants that worked here and failed in the clinic is long. They are not to be waved away, but not to be read as prediction either.
Against that stands one finding that does not come from a toxin model. In 2018 Graham and colleagues injected α-synuclein fibrils into the olfactory bulb of mice, after which the clumps spread through the brain on their own, and then went looking at which metabolic pathways in that brain were most disturbed. Taurine and hypotaurine metabolism came out on top.25 No taurine was administered in that experiment, so it says nothing about treatment. What it does do is make taurine surface in a model where nobody poisoned the brain.
No experiment in this part gave taurine to a human being.
Absorbed up top, and what is left further down
Taurine is not a store sitting still inside you. It flows through — and your gut sits in the middle of that flow.
Your liver attaches taurine to bile acids so you can digest fat. That bile goes into your gut. There, bacteria cut the taurine back off.
Some gut bacteria breathe that taurine. They burn it and turn it into hydrogen sulfide — the gas you know from rotten eggs.
The tempting thought is: those bacteria are eating my taurine, so less of it is left for my brain. That is not how it works.
The taurine you swallow is absorbed high up in your small intestine, long before any bacterium can reach it. What ends up in your colon gets there by a detour: your liver uses taurine to make bile, and about 5% of that bile escapes reabsorption and arrives further down after all.
So the question is not how much taurine you have left. The question is where it ends up — and what happens to it in that place.
Hydrogen sulfide has a bad name, and it is only half deserved. Your body makes it deliberately, with three enzymes that do nothing else — it is a signalling molecule in the same category as nitric oxide, regulating your blood vessels, your defence against oxidative stress and your mitochondria.
Taurine and hydrogen sulfide are also literally family: cysteine is the raw material for both, and at a single fork one branch runs to taurine and the other to the gas.
So it is not about the compound. It is about who makes it, where, and how much. Your own enzymes make small amounts, in the right place, with a tap on it.
Bilophila wadsworthia does the reverse. That bacterium breathes taurine, down at the bottom of your gut, in bulk and with no tap — give a mouse extra taurine-conjugated bile acid and it blooms; with glycine-conjugated bile acid it does not. And above a certain amount the gas shuts down the energy metabolism of your gut cells and breaks the sulfur bridges in your mucus layer. Precisely the layer that protects your gut wall.
Up top it ends differently, and that has been measured in humans. In the blood pressure trial from the start of this piece, the participants who took taurine for twelve weeks ended up with not only more taurine in their blood but also twice as much hydrogen sulfide — from 44 to 87 — and the further those two had risen, the further their blood pressure had fallen. On the dummy capsule neither happened.5
The same molecule, then: in bulk at the bottom of the gut an assault on the mucus layer, in the blood apparently the route along which a favourable effect runs.
There is nothing you can do about your substantia nigra, nothing about your blood-brain barrier, and nothing directly about the inflammatory setting of your microglia.
Which bacteria hold the majority in your colon, you can — through what you feed them. Fermentable fibre lowers the pH, lets butyrate producers win and pushes back the sulfur route. In human interventions Bilophila did indeed fall.
And it goes further than that one bacterium. Compare people who eat plenty of fibre and little fat with people doing the reverse, and the first group makes more bile acid with glycine attached — precisely the variant the sulfur breathers have no use for — and excretes less bile acid in total.
What did not happen: the taurine-conjugated bile acids in their blood were not lower. So fibre apparently does not take away the sulfur breathers’ food, but changes who is standing ready to eat it.
How to do that, and why some fibres are far better at it than others, is what a whole other article is about: how acacia fibre acidifies the colon.
Evidence
The absorption side first, because everything else hangs on it. Oral taurine is absorbed high up in the small intestine, with a plasma peak at an hour and a half; the transporter doing most of that work is the low-affinity, high-capacity PAT1 alongside the high-affinity TauT, and in rats absorption stayed not saturable across 10–997 mg/kg.26,27,28 So you cannot “dose” taurine into your colon by taking more of it. The colonic route runs through bile: roughly 95% of conjugated bile acids are reabsorbed in the terminal ileum, and the remaining ±5% reaches the colon, where bacterial bile salt hydrolase cleaves the taurine off.29
That this route really works this way has been shown most sharply through diet. Mice on a diet rich in milk fat produced more taurine-conjugated bile acid, upon which B. wadsworthia bloomed and Il10−/− mice developed colitis. The decisive experiment: supplementing taurocholic acid did it, glycocholic acid did not.30 So it is specifically the taurine conjugation that feeds the sulfur breathers.
And then there is the other side: taurine-driven sulfide is not simply bad. Taurine supplementation in mice strengthened the gut flora’s resistance to Klebsiella pneumoniae and Citrobacter rodentium, demonstrably through sulfide production.31 The distinction is apparently one of quantity. In cultured human colonic cells the threshold sits at 50 µM: above it respiration falls, below it the cells oxidise the sulfide away themselves.32 In colonocytes from human surgical specimens, sulfide inhibited butyrate oxidation but not glucose oxidation33, and in mice sulfide breaks the disulfide bridges in mucin, opening up the mucus layer.34
That bacteria breathing on taurine exist is solid: a taurine-respiring species in the mouse gut has been described that depends on other bacteria to release taurine from bile acids, and whose colonisation in turn increases that deconjugation.35 In the human gut, B. wadsworthia is the best-known member of that guild — the same species that forms the fourth sulfur route in the fibre piece.
Since April 2026 there is a mechanistic explanation for the specificity Devkota could only observe. B. wadsworthia turns out to have its own secreted enzyme — a metal-dependent bile salt hydrolase outside the known enzyme family — with specific activity toward taurine-conjugated bile salts. It is conserved within the species and occurs in many other Desulfovibrionaceae. So the sulfur breather does not wait for another bacterium to free its substrate; it cuts it loose itself, and selectively.36 This is a preprint without peer review, so no step in the account above rests on it — it merely explains neatly what had already been measured.
Against that stands the endogenous side. You make H₂S yourself, with CBS, CSE and 3-MST, and it behaves as a gasotransmitter that regulates your antioxidant defence, your vascular function, your inflammatory response and your mitochondria — and it happens that dysregulation of that transsulfuration pathway has been described precisely in Parkinson’s, Huntington’s and Alzheimer’s.37
And then the finding that shows most sharply how much this is a story about place: H₂S donors are neuroprotective in the same Parkinson models. NaHS restored motor function in 6-OHDA and rotenone models, preserved TH-positive neurons in the substantia nigra and inhibited microglial activation via NF-κB; the slow-releasing donor GYY4137 did the same in the MPTP model.38 That is exactly the mechanism by which taurine worked in PART II. The same molecule, the opposite outcome, and the difference lies in place, dose and regulation.
In humans that step has been measured once, and not in Parkinson’s research. In the prehypertension trial, plasma taurine in the taurine group rose from 108.3 to 142.3 µmol/L and plasma H₂S from 43.8 to 87.0 µmol/L, and the change in blood pressure correlated negatively with both; in the placebo group neither happened.5 Two changes moving together are not a demonstrated route, and a blood pressure trial is no model of this disease. What is there is a measurement in humans in which swallowed taurine raised the sulfide while the outcome went the right way.
Biochemically the two are literally related: cysteine catabolism splits into an oxidative route via cysteine dioxygenase to taurine and sulfate, and a non-oxidative route via CBS, CSE and 3-MST to H₂S.39
In the rotenone model they measured that shift directly as well. Taurine largely undid the dysbiosis the toxin had caused, and at the same time gut motility came back, and the barrier function of both the intestine and the blood-brain barrier, and LPS, IL-1β, IL-6 and TNFα fell in plasma.17 That is the gut-brain axis in a single experiment, but without a faecal transplant or germ-free control it again stays unresolved whether the gut carries the protection or merely moves along with it.
There is a second thread between fibre and this route, and it is counter-intuitive. In rats, pectin dose-dependently raised bile acid excretion, but that increase consisted entirely of glycine-conjugated bile acid while the taurine conjugates fell — precisely the conjugation that, per Devkota, does not feed Bilophila. The explanation is that the raised bile acid excretion draws on the hepatic taurine store, after which the liver switches to glycine.40
This is visible in humans too, though cross-sectionally rather than by intervention. In 36 vegans against 36 omnivores — more fibre, less fat — serum primary and glycine-conjugated bile acids were in fact higher and all faecal bile acids lower. In the pattern analysis fat intake correlated positively and fibre intake inversely with the bile acids; that pattern explained 47.4% of the variance.41
But the comparison with Ide only half holds, and that emerges only from the full text: serum taurine-conjugated bile acids did not differ between vegans and omnivores. What was measured is an increase on the glycine side, not a shift away from taurine. In the rat the taurine conjugates did fall; in these people they did not. Fibre apparently does not remove the sulfur breathers’ food. Further: cross-sectional, not randomised, and vegans differ in more than fibre alone.
The individual foods from that pattern analysis say less than they appear to. Loading positively on the bile acid pattern were not only processed meat, fried potatoes and margarine but also fish and coffee — so it is not a healthy-versus-unhealthy axis. And what loaded most negatively was muesli, which in a German cohort of 72 people probably flags the whole group rather than doing anything itself — though that is a reading, not a measurement. Loadings in a pattern analysis are not dietary advice. What the study did find are associations: fat intake positively, fibre intake inversely.
Fibre moreover raises the flora’s deconjugation capacity, and that works the other way: whole food intake went together with more bile salt hydrolase activity and with fewer conjugated bile acids in stool, supported by a fibre-free intervention in healthy people.42 More deconjugation means the taurine is in fact freed faster. So fibre does not remove the substrate — it changes who is standing ready to eat it. That is the same conclusion as above, now from a third direction.
The catch belongs right alongside it, because it is in the same study: when those rats were given taurine as well, glycine conjugation was all but abolished and taurine conjugates dominated again. Fibre plus taurine simply yields taurine-conjugated bile again. The protection fibre offers therefore lies not in less substrate but in fewer sulfur breathers to eat it. (Rat, 1989, and one kind of fibre — pectin, not acacia; this is mechanism, not a dosing recommendation.)
That you can steer this has been measured in humans, if modestly: in fibre and prebiotic interventions the abundance of B. wadsworthia fell, among them the BE GONE bean trial, and in one prebiotic study that decrease persisted two weeks after stopping.43
For completeness, the Parkinson’s part of this axis. In mice with an MPTP model, Lactobacillus, Lachnospiraceae and Adlercreutzia were reduced and Aerococcus, Staphylococcus and Ruminococcaceae raised, while serum taurine had clearly fallen; adding taurine (150 mg/kg daily, four weeks) restored movement, protected dopamine neurons and reduced microglial activation.20 The weak link right alongside it: no faecal transplant was done. Both fall together, and which one is driving is unresolved.
Bile acids in Parkinson’s, and bile acids in illness
There is one finding that points the wrong way, and it comes from the longest-running human research there is.
In people followed for four years, three taurine-containing bile acids tracked worse motor symptoms. The more of them, the worse.
It was an observation, not an experiment. Those raised taurine-conjugated bile acids came from their own bodies and their own gut flora, not out of a tub.
What sets your liver to taurine?
Your liver hangs either glycine or taurine on every bile acid. This is what pushes that choice towards taurine, in order of how heavily it weighs.
- Being ill as such. In 70 patients with severe lung failure the ratio shifted towards taurine in proportion to the severity score, and it predicted who pulled through. The researchers read that as the body adapting to illness.44
- A liver under strain. In chronic liver disease this ratio shifts so reliably that you can stage the disease with it.45
- Saturated fat. Mice on a diet rich in milk fat produced more taurine-conjugated bile acid — precisely the experiment in which Bilophila bloomed.30
- Little fibre. The same from the other side: in rats, pectin pushed conjugation towards glycine instead.40
- And taking taurine. 250 mg straight into the small intestine raised the share of taurine-conjugated bile acid in seven of ten subjects, by two and a half to ten percentage points — without the pool that circulates day in, day out shifting acutely because of it.46
The severity of the symptoms. Exactly the relationship found in every other disease too — being ill as such is the very thing that throws the switch towards taurine hardest.
In this cohort one more thing comes on top: Bilophila was raised as well, and more taurine-conjugated bile acid plus more sulfur breathers fits a gut that burns taurine instead of letting it through. None of these readings is proven. But “taking taurine makes Parkinson’s worse” is the one for which you have to ignore all the others.
Less saturated fat and more fermentable fibre are the two you can act on today, and they push the same way: towards bile acid with glycine attached, and towards a flora in which the sulfur breathers end up in the minority. Fibre changes nothing about a diseased liver or about how far your Parkinson’s has progressed, and those are precisely the two that weigh heaviest.
Evidence
This is the DeNoPa cohort: 30 drug-naïve, newly diagnosed patients and 30 matched controls, followed with measurements at baseline, 24 and 48 months. Three taurine-conjugated bile acids were positively associated with the UPDRS-III score. In a separate population cohort, sulfated taurolithocholic acid was instead protectively associated with the incidence of Parkinson’s — so even within this family the metabolites do not point the same way.47
In the same work Bilophila wadsworthia and Akkermansia muciniphila were raised in Parkinson’s, with consequences for sulfite and H₂S production, and cystathionine accumulated in the sulfur route.47 That is the same axis as in PART III — and it makes the most natural reading not “taurine is bad” but these guts convert taurine into sulfide instead of passing it on.
This is an interpretation consistent with the known biochemistry, not a demonstrated link. The cohort was not designed to establish direction, and nobody measured whether sulfide was actually higher in these people. Anyone who prefers to read the finding as crossing out the whole taurine story is, on these data, equally entitled to do so.
There is moreover a confound that weighs heavier than the gut reading, and it comes from outside Parkinson’s research entirely. The glycine:taurine ratio of conjugated bile acids shifts towards taurine in illness generally. In 70 ARDS patients that ratio was substantially lower than in healthy controls — 1.79 against 3.80 — and specifically because of an increase in the taurine conjugates; it correlated with the SAPS II severity score and with survival, and the authors explicitly read it as an adaptive response to illness.44 In chronic liver disease, glycine:taurine ratios are so stage-specific that diagnostic models built on them reach an AUC of 0.91 to 0.97 in a cohort of 1883 participants.45
Set that beside the finding: in DeNoPa the taurine conjugates tracked the UPDRS-III — a severity measure. A marker that moves with severity in illness generally also moves with severity here. That is exactly what you expect of a consequence, and it cannot be told apart from a cause in a design without an intervention.
And then the question that actually matters to a reader: how solid is the bridge between taking taurine and taurine-conjugated bile acid? Weaker than you might think, but not nil. In humans, hepatic taurine concentration is the main determinant of the percentage of bile acids conjugated with taurine, and as little as 250 mg of intraduodenal taurine raised that percentage by 2.5 to 10 percentage points in 7 of 10 subjects within two and a half hours. That same study explicitly adds that the deviation is small and that the composition of the circulating bile acid pool does not change acutely.46
Taken together: this is a cross-section without an intervention, in which the exposure (taurine-conjugated bile acid) is at best indirectly and weakly coupled to what someone swallows. As evidence against supplementation it is therefore weak; as an indication that a sulfur-heavy gut shows up in the bile acid profile it weighs more.
Nobody in that four-year Parkinson’s study was taking taurine.
How much gets there?
The question you expect here is: does a capsule even reach your brain? That is no longer the question, and it has not been for a few years now.
The human brain actively takes taurine out of the blood. In 28 people, blood from a vein behind the brain was compared with blood from an artery in front of it — whatever the brain takes out has to show up in that difference — and of 1,365 compounds measured, taurine was among the three with the highest net uptake, alongside glucose.
And swallowed taurine does reach the spinal fluid: in four people given taurine by mouth, the level in their spinal fluid was measurably higher.
So the door is narrow and regulated, but it demonstrably stands open. The open question is not whether, but how much.
Evidence
The limitation first, because it is real. Transport across the blood-brain barrier runs via the taurine transporter TauT (SLC6A6) and is saturable. At raised plasma levels the transporter is downregulated, and under oxidative stress and in disease states the transport works less well — exactly the circumstances in which you would want it.48 That bounds how much gets in. It does not close the route.
That the route is open has now been measured in humans. In blood from the cerebral venous sinus against arterial blood, taurine ranked with glucose and hypoxanthine among the compounds with high net uptake by the brain — out of 1,365 metabolites and 140 lipids.49 The participants had sinus stenosis or thrombosis, because that vein is only reachable by catheter; it was neither a supplementation nor a Parkinson’s study.
And oral intake demonstrably reaches the central nervous system. In an open-label trial in SSADH deficiency, spinal fluid taurine was elevated during oral treatment, in the four participants from whom fluid was available.50 That trial was clinically negative — no cognitive gain, and the TMS outcome ran against the hypothesis. Different disease, different endpoint; what follows from it here is solely the transport fact.
That spinal fluid and brain tissue are not the same thing shows up in the animal. Rats given taurine for fourteen days held the same total amount of taurine in their brains.51 Probably the throughput rises while the pool inside the cell stays regulated — which is what you would expect of a saturable transporter. Anyone hoping to fill their brain with taurine is hoping for something no one has measured.
At high doses there is even a human chain from capsule to molecular target. Ten people with MELAS took 9 to 12 grams a day for 52 weeks; the taurine modification of their mitochondrial tRNA rose in five of them and the annual rate of stroke-like episodes fell from 2.22 to 0.72.52 That modification was measured in white blood cells and not in brain tissue, the trial was open with no placebo, and the dose is a factor of ten above the one at issue here.
What remains is therefore a narrower uncertainty than “does it get there”: how much brain exposure roughly 850 mg a day produces in someone with Parkinson’s, and whether that is enough. No measurement of that exists. Beyond it, part of this story plays out outside the brain anyway — the gut route from PART III and systemic anti-inflammatory action — but that is reasoning, not measurement.
Taurine in the striatum, taurine in the nigra
That claim circulates widely, and it is too simple. When they infused taurine straight into the striatum of rats, extracellular dopamine rose — 2.5-fold at 150 mM over two hours, and 10-fold at 450 mM, but then only in the first half hour. When they put the same taurine a little further along, in the substantia nigra, striatal dopamine fell instead.53
The effect therefore depends on where the compound ends up, at concentrations that have nothing to do with swallowing. “Taurine raises dopamine” is not a property of taurine. Nowhere does the story here run through dopamine; it runs through inflammation.
Not measured: how much reaches the brain at 850 mg a day.
Blood pressure, blood sugar, and a prescription in Tokyo
A hundred and twenty people whose blood pressure sat just under the threshold took 1.6 grams of taurine a day for twelve weeks, or a dummy capsule, and nobody knew who got which. Measured in the clinic, the upper reading fell 7.2 points in the taurine group and 2.6 in the other.5
Now suppose the Parkinson’s story comes to nothing. Then you will have taken something that lowers your blood pressure, improves your blood sugar, and is prescribed as a medicine in Japan.
So you do not have to bet on the indication, because you lose nothing if it does not pay off.
Approved for congestive heart failure, for improving liver function in hyperbilirubinaemia, and for preventing stroke-like episodes in MELAS. Dosage: 1 gram, three times a day, after meals.
Japanese drug information · Taurine Powder 98% “Taisho”The same molecule, the same dose, the same literature. In Tokyo a cardiologist prescribes it; in the Netherlands it sits in a tub at the chemist, among the multivitamins.
Evidence
Unlike Parkinson’s, here there is straightforward randomised evidence in humans. A meta-analysis of 25 trials with 1024 participants found a fall in systolic pressure of about 4.0 mmHg and in diastolic of 1.5 mmHg, plus a dose-dependent improvement in fasting glucose.6 To be precise: −4.00 mmHg (95% CI −7.29 to −0.71), −1.51 mmHg (−2.48 to −0.54) and −5.88 mg/dl fasting glucose (−10.75 to −1.02), at doses from 0.5 to 6 g/day and durations from five days to a year. There is a second meta-analysis you often see cited alongside it, but that is not an independent confirmation: both from Tzang and colleagues, both from 2024, and a systolic estimate identical to three decimal places. That one counts 20 trials and 808 participants and comes out at −1.44 mmHg diastolic.54 In heart failure, clinical doses of 500 mg to 6 g per day have been used, though the systematic review that collected them found no significant association for ejection fraction or stroke volume.55
The broadest and most recent meta-analysis — 34 trials — arrives at comparable values: −4.38 mmHg systolic, −2.54 diastolic, and −5.90 mg/dl fasting glucose.56 Only the abstract of it was available.
The trial this part opens with comes with a little more detail. Of the 120 randomised participants, 86 were analysed, 44 on placebo and 42 on taurine. The fall of 7.2 against 2.6 mmHg is the clinic measurement, and that is the measurement on which the comparison between the two groups reached significance, at 8 and at 12 weeks. Measured across a whole day with an ambulatory monitor, the upper reading fell 3.8 mmHg against its own baseline while the placebo group went up 0.3, and the lower reading 3.5 against 0.6. Smaller, then, and on a different kind of test. Those who started highest fell furthest: with a high-normal starting pressure (130–139/85–89) it came down 10.1 mmHg against 3.0 in the low-normal group.5
A formal upper limit does not exist. No systematic pattern of adverse effects surfaced in humans, so there was nothing to base a NOAEL on, and Shao and Hathcock arrived instead at what they call an observed safe level — 3 g/day for healthy adults, which is to say the highest dose at which they saw nothing happen.9 The Norwegian regulator went into more detail and assessed individual supplement doses: 750, 800, 900 and 1000 mg a day it considers unlikely to harm adults, while 2000 mg a day may represent a risk.8
Two things on that. The 850 mg from the animal-dose conversion falls exactly inside the range that was assessed directly — more useful than a distant ceiling. But the margin is not unlimited: between that dose and the point where VKM sees a risk lies a factor of two. And the Japanese medicine at 3 grams a day sits above what VKM holds for supplements. That is not a contradiction — a prescription drug is supervised and a tub from the chemist is not — but the two situations are not interchangeable either.
And there is a real deficiency side. Plants contain no taurine; vegans had a plasma level of 45 against 58 µmol/l in omnivores, and excreted far less of it in urine: 266 against 903 µmol per day.3
The authors themselves take it that the body probably becomes more frugal and makes enough. So it is a lower level rather than a demonstrated harmful deficiency: people eating plant-based sit consistently lower, and whether that harms them has not been measured.
Of the aging claim that made this subject popular, little survives re-measurement. A Canadian group measured circulating taurine in 137 men aged 20 to 93 and found no association at all: not with age, and not with muscle mass, strength, physical performance or mitochondrial function.57
The 2023 taurine hype, and what happened to it in 2025.
The entire taurine wave started with a 2023 Science paper claiming that taurine declines with age and that topping it up slows ageing.58 In 2025 Fernandez and colleagues, at the National Institute on Aging within the NIH, measured taurine in people aged 26 to 100, in rhesus monkeys and in mice — and found it does not reliably decline with age. In most groups it rose or stayed flat, and the variation within a single person often exceeded the change with age.59 So “taurine falls as you get older” is no longer a settled fact. The Parkinson’s story is separate from it: that was measured in spinal fluid in sick people, not in blood in old people.
Practical
The 150 mg/kg that worked in the mouse studies converts, by the usual body-surface scaling, to roughly 850 mg for someone of 70 kilos.
That 150 mg/kg went in by injection in Che’s work, and that is not what you would do. Nor does it have to be: Moon and colleagues gave their mice the taurine simply in the drinking water, 250 or 1000 mg/kg a day, for a month, and saw the dopamine neurons preserved all the same.16
That is less than the Japanese medicine (3 grams) and it falls in the middle of the 750 to 1000 mg the Norwegian regulator assessed directly as unlikely to harm adults. From food you get around 150 mg. More is not better: at 2000 mg a day that same regulator does see a possible risk.
In other words: the dose is not the problem. Whether enough of it arrives in the brain is the problem.
Anyone on levodopa knows the rule that you must be careful with protein around your dose, and that is a real interaction with a known cause.
The reason is that levodopa is itself a large neutral amino acid. It competes with leucine, valine, phenylalanine and a few others for the same transporter — in your gut wall and at your brain barrier. Too much protein at once and less levodopa arrives.
Taurine takes no part in that fight. It does not belong to that group and uses an entirely different transporter.
There is no reason to expect taurine to get in the way of your levodopa, and that is not the same as having shown it to be safe alongside it.
Evidence
Levodopa is structurally related to phenylalanine and tyrosine and is transported by LAT1 (SLC7A5–SLC3A2), both across the gut wall and across the blood-brain barrier. The seven large neutral amino acids — leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan and methionine — compete for the same seats, which is why protein intake is timed around dosing.60
Taurine is not a large neutral amino acid and not a substrate of LAT1; it uses TauT (SLC6A6).48 On that basis, competition at the LAT1 gate is not to be expected. That is an inference from transport pharmacology, not an interaction study. I found no research measuring taurine and levodopa absorption together.
The reverse has been measured, and there is an open question here: levodopa use goes together with lower plasma taurine, in proportion to the cumulative dose.13
Taurine has to be absorbed up top, in your small intestine. What is absorbed there reaches your blood. What your gut flora gets hold of becomes sulfur gas.
There is a second way to end up in the wrong place, and it runs the other way: too early. With small intestinal bacterial overgrowth — SIBO — there are bacteria up top where they do not belong, and they take your bile apart before it has been able to do its job, so the taurine is released right in the stretch of gut where you wanted to absorb it. Your fat digestion goes wrong at the same time.
The difference is in the timing. A sulfurous smell comes from down below, and later. Symptoms soon after eating, poor tolerance of fat, pale or greasy stools: that points higher up, and it belongs with your doctor.
Does the taurine land in the right place?
Do not push through symptoms — even though the symptom is not a measurement.
- Start low and spread it over the day. There is a reason the Japanese medicine is 1 gram three times a day and not 3 grams at once.4
- Use your nose. A sulfurous smell means taurine is reaching your gut flora and being burned into H₂S there.32
- If that happens: stop building up. Pushing on feeds the sulfur breathers and strains your mucus layer. This is not something you get used to.
- Symptoms soon after eating, or poor fat tolerance? Think overgrowth higher up rather than your colon — that calls for a different approach, and for a doctor.61,62
- Work on your gut flora first. Fermentable fibre, built up slowly, lowers the pH and pushes back the sulfur route. How to go about it is in the piece on acacia fibre.43
- Then try taurine again. The same dose can behave completely differently in a different gut.
Two things alongside all this.
Taurine also simply stimulates bile production, and that alone can loosen stools without much sulfide being involved. Your nose can tell the two apart: the sulfur route you smell, a bile stimulus you do not.
Anyone without a gallbladder, on bile-acid-binding medication, or with a known bowel disease should discuss this with their doctor first. With active gut inflammation, extra sulfide is the last thing you want.
In closing
The indication, and the gut
In people with early Parkinson’s, taurine is lower in the spinal fluid, and within that group more taurine tracks a more favourable scan and fewer limitations. In mice taurine keeps dopamine neurons alive, and in a separate cell culture that stops as soon as you remove the microglia.
The supply side has now been measured too: the human brain takes up circulating taurine on balance, and oral intake raises taurine in the spinal fluid. What nobody has measured is the last step — whether roughly 850 mg a day delivers enough in Parkinson’s to matter. Until that study exists, it stays an indication.
But there is something you can turn, and it is not the taurine. It is the gut that decides whether taurine passes through or gets burned into sulfur gas — and anyone who smells that gas probably has more to gain from starting there than from raising the dose.
There is little to lose by not waiting. It is a compound your body makes itself, that goes on prescription in Japan, that lowers blood pressure across dozens of trials, and whose stated dose has been assessed directly as unlikely to cause harm. Waiting for a trial that may never be run is a judgement too, and anyone making it the other way round has just as good reasons.